© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
Dermatology
FDA Approves Dupilumab for Atopic Dermatitis in Children
May 26, 2020
Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.
Phase 3 Study: Apremilast Shows Efficacy in Mild-to-Moderate Plaque Psoriasis
May 08, 2020
Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.
FDA OKs Crisaborole for Use in Children as Young as 3 Months of Age
March 24, 2020
Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.
Abrocitinib Improves Moderate-to-Severe Atopic Dermatitis in Phase 3 Study
March 23, 2020
Phase 3 clinical data demonstrate abrocitinib’s efficacy and safety in treating moderate-to-severe atopic dermatitis in adults.
New Phase 3 Data on Baricitinib Efficacy in Atopic Dermatitis
February 04, 2020
Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.
FDA Grants Priority Review to Dupilumab for Children with Atopic Dermatitis
January 28, 2020
If approved, dupilumab (Dupixent, Regeneron and Sanofi) would be indicated for use as an add-on maintenance treatment for children ages 6 to 11 years with moderate-to-severe atopic dermatitis.
What Pharmacists Need to Know About Psoriasis Medications
January 17, 2020
Pharmacists can play an integral role in managing patients with psoriasis through medication therapies and lifestyle modifications.
Minocycline Topical Foam 4% Approved by FDA for Acne Vulgaris
October 21, 2019
Available for prescribing starting January 2020
Cetirizine IV Approved for Pediatric Acute Urticaria
October 18, 2019
Originally approved in 1995 for use in adults only.
FDA Approves Trifarotene Cream for Acne Treatment
October 08, 2019
First new treatment of its kind in over 20 years.